Cargando…

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

Detalles Bibliográficos
Autores principales:	Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dent, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707946/ https://www.ncbi.nlm.nih.gov/pubmed/31489122 http://dx.doi.org/10.18632/oncotarget.27162

Ejemplares similares

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration
por: Booth, Laurence, et al.
Publicado: (2017)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
por: Booth, Laurence, et al.
Publicado: (2017)

HDAC inhibitors enhance the immunotherapy response of melanoma cells
por: Booth, Laurence, et al.
Publicado: (2017)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
por: Roberts, Jane L., et al.
Publicado: (2021)

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide
por: Booth, Laurence, et al.
Publicado: (2016)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]
por: Booth, Laurence, et al.
Publicado: (2017)

The calcium‐sensing receptor: A novel target for treatment and prophylaxis of neratinib‐induced diarrhea
por: Lysyy, Taras, et al.
Publicado: (2019)

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic
por: Tavallai, Mehrad, et al.
Publicado: (2016)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021)

Fingolimod Augments Monomethylfumarate Killing of GBM Cells
por: Dent, Paul, et al.
Publicado: (2020)

Corrigendum: Fingolimod Augments Monomethylfumarate Killing of GBM Cells
por: Dent, Paul, et al.
Publicado: (2020)

Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+ve) breast cancer metastasis
por: Nagpal, Aadya, et al.
Publicado: (2019)

Neratinib for breast cancer
Publicado: (2019)

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies
por: Dent, Paul, et al.
Publicado: (2019)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
por: Alkhezayem, Sara, et al.
Publicado: (2020)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer
por: Ribas, Ricardo, et al.
Publicado: (2018)

Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43
por: Dent, Paul, et al.
Publicado: (2021)

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS
por: Tavallai, Mehrad, et al.
Publicado: (2016)

AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication
por: Rayner, Jonathan O., et al.
Publicado: (2020)

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species
por: Roberts, Jane L., et al.
Publicado: (2017)

Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2016)

AR12 increases BAG3 expression which is essential for Tau and APP degradation via LC3-associated phagocytosis and macroautophagy
por: Dent, Paul, et al.
Publicado: (2022)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
por: Oaknin, Ana, et al.
Publicado: (2020)

Kinase inhibitors: look beyond the label on the bottle
por: Dent, Paul, et al.
Publicado: (2019)

OSU‐03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood–Brain Barrier: Implications for Anti‐Cancer Therapies
por: Booth, Laurence, et al.
Publicado: (2015)

Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells
por: Tavallai, Mehrad, et al.
Publicado: (2015)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
por: Liu, Junjie, et al.
Publicado: (2022)

Neratinib protects pancreatic beta cells in diabetes
por: Ardestani, Amin, et al.
Publicado: (2019)

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
por: Chia, Stephen K. L., et al.
Publicado: (2019)

Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy
por: Cruickshanks, Nichola, et al.
Publicado: (2013)

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
por: Han, Rui, et al.
Publicado: (2023)

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
por: Booth, Laurence, et al.
Publicado: (2016)

Profile of neratinib and its potential in the treatment of breast cancer
por: Feldinger, Katharina, et al.
Publicado: (2015)

Neratinib-Induced Duodenal Ulcer: A Case Report
por: Moftakhar, Bahar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q1ln5jj7lhgg9oehjjki16d3ht